Study S001939

A Phase 3 Randomized, Double-Blind, Placebo-Controlled, 78-Week Efficacy and Safety Study of VK2735 Administered Subcutaneously for Weight Management in Participants Without Type 2 Diabetes Who Are Obese, or Overweight With at Least One Weight-related Comorbid Condition

ClinicalTrials.gov record

Registration

Registration: NCT07104500
Acronym: VANQUISH 1
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: TRIPLE
Status: ACTIVE_NOT_RECRUITING
Enrollment: 4500
Start: 2025-06-23
Primary completion: 2027-07-01
Lead sponsor: Viking Therapeutics, Inc.
Conditions: Weight Loss
Interventions: DRUG:VK2735
Results posted: FALSE

Registered primary outcomes

Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment [78 Weeks]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.